ABY 029

Drug Profile

ABY 029

Alternative Names: ABY-029 trifluoroacetate salt; fluorescently-labeled Anti-EGFR affibody molecule; IRDye 800CW maleimide-labeled affibody peptide

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affibody; Dartmouth College; LI-COR Biosciences
  • Developer Dartmouth College
  • Class Imaging agents; Peptide diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Epidermal growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Glioma

Most Recent Events

  • 20 Sep 2017 Dartmouth-Hitchcock Medical Center plans a phase I trial for Head and neck cancer in USA (NCT03282461)
  • 23 May 2017 Dartmouth College plans a phase 0 trial for Soft-tissue Sarcoma (Diagnosis) in USA (NCT03154411)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top